What is the expected platelet count in a patient with Henoch‑Schönlein purpura (IgA vasculitis) presenting with the classic rash, abdominal pain, arthralgia, and possible renal involvement?

Platelet Count in Henoch-Schönlein Purpura (IgA Vasculitis)

Expected Platelet Count

In Henoch-Schönlein purpura, the platelet count is characteristically normal or elevated—never low—which is a critical diagnostic feature that distinguishes HSP from immune thrombocytopenic purpura and other thrombocytopenic disorders. 1

The purpuric rash in HSP is non-thrombocytopenic, meaning it occurs despite normal platelet numbers, because the vascular inflammation and leakage are caused by IgA-mediated small-vessel vasculitis rather than platelet deficiency 1.

---

Platelet Count Patterns in HSP

Normal to Elevated Range

• The majority of HSP patients maintain platelet counts within the normal reference range (150,000–400,000/µL) 2, 3.
• Thrombocytosis (platelet count >400,000/µL) occurs in 60–70% of HSP patients, representing a reactive inflammatory response rather than a primary hematologic abnormality 2.

Mechanism of Thrombocytosis

• Elevated platelet counts in HSP represent inflammatory reactive thrombocytosis mediated by interleukin-6 (IL-6) and other inflammatory cytokines, not by thrombopoietin (TPO) 2.
• Serum IL-6 levels are significantly elevated during the acute phase of HSP (28.6 ± 61.7 pg/mL vs. 3.16 ± 1.35 pg/mL in controls), driving the reactive platelet elevation 2.
• TPO levels in HSP patients—whether thrombocytotic or not—remain similar to healthy controls, confirming that thrombocytosis is cytokine-driven rather than TPO-mediated 2.

---

Clinical Significance of Platelet Parameters

Platelet Count as a Predictor of Renal Involvement

• Higher platelet counts are significantly associated with renal involvement in HSP (mean platelet count higher in patients with nephritis vs. those without, P = 0.001) 3.
• Multivariate analysis identified platelet count as an independent risk factor for HSP nephritis (odds ratio 1.0, area under the curve 0.66, P = 0.009) 3.
• Other independent predictors of renal involvement include older age, male sex, and gastrointestinal involvement 3.

Mean Platelet Volume (MPV) Patterns

• MPV is significantly lower in HSP patients compared to healthy controls (8.1 ± 0.86 fL vs. 9.4 ± 0.81 fL, P < 0.001), reflecting increased platelet consumption and turnover during active vasculitis 4.
• MPV is inversely correlated with disease activity: acute-phase HSP patients have lower MPV than convalescent-phase patients (7.8 ± 0.86 fL vs. 8.3 ± 0.77 fL, P = 0.002) 4.
• An MPV cutoff of 7.85 fL distinguishes acute from convalescent HSP with an area under the curve of 0.726 4.
• MPV is significantly higher in HSP patients with renal involvement compared to those without nephritis (P = 0.027), suggesting that MPV may help stratify risk for kidney complications 5.

Neutrophil-to-Lymphocyte Ratio (NLR) and Gastrointestinal Bleeding

• NLR is significantly elevated in HSP patients with gastrointestinal bleeding compared to those without GI involvement (P < 0.001) 5.
• An NLR cutoff of 2.05 predicts gastrointestinal bleeding with 93% sensitivity and 62% specificity 5.

---

Diagnostic Algorithm

1. Confirm Non-Thrombocytopenic Purpura

• Obtain a complete blood count with peripheral smear to document normal or elevated platelet count (typically 150,000–600,000/µL) 2, 3, 1.
• The presence of thrombocytopenia (platelet count <100,000/µL) excludes HSP and mandates evaluation for immune thrombocytopenia, thrombotic microangiopathy, or bone-marrow disorders 6.

2. Assess for Thrombocytosis and Inflammatory Markers

• Platelet counts >400,000/µL occur in 60–70% of HSP cases and correlate with disease severity 2.
• Measure erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), which are typically elevated during active disease 5, 4.

3. Evaluate MPV and NLR for Risk Stratification

• Low MPV (<7.85 fL) indicates acute-phase disease and higher inflammatory activity 4.
• Elevated MPV suggests increased risk of renal involvement and should prompt urinalysis, urine protein-to-creatinine ratio, and renal function testing 5.
• NLR >2.05 predicts gastrointestinal bleeding and warrants close monitoring for abdominal pain, melena, or hematochezia 5.

4. Monitor for Complications

• Serial platelet counts, MPV, and NLR can track disease activity and response to therapy 4.
• Persistent thrombocytosis or rising platelet counts may signal ongoing inflammation or impending renal involvement 3.

---

Critical Pitfalls to Avoid

• Never diagnose HSP in the presence of thrombocytopenia—the purpura in HSP is non-thrombocytopenic by definition, and low platelet counts indicate an alternative diagnosis such as ITP, TTP, or bone-marrow failure 1.
• Do not dismiss elevated platelet counts as incidental—thrombocytosis in HSP reflects active inflammation and correlates with higher risk of renal complications 2, 3.
• Do not overlook MPV as a disease-activity marker—low MPV during the acute phase and rising MPV during recovery can guide treatment decisions and follow-up intervals 4.
• Do not ignore NLR elevation—an NLR >2.05 is highly sensitive for gastrointestinal bleeding and should prompt aggressive monitoring and early intervention 5.